Advanced Filters
noise
Found 2,238 clinical trials

An Ophthalmic Safety Study in Patients With Breast Cancer

To assess ophthalmic health in parallel cohorts of patients with breast cancer

18 - 130 years of age All Phase N/A
Y Young-Joon Kang, PhD

Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study

Breast cancer, the most prevalent malignancy among women globally, is increasing in incidence. While non-metastatic breast cancer requires surgery, determining the optimal extent of resection remains challenging. Inadequate resection margins necessitate reoperation, leading to increased psychological stress, costs, and potentially compromised cosmetic outcomes and prognosis. Accurate preoperative assessment of resection …

19 years of age All Phase N/A

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk to recurrence and metastasis. After the appearance of anti-HER2 targeted drugs, the prognosis and survival of these patients were greatly improved. In addition to trastuzumab and pertuzumab, the use of …

years of age All Phase N/A
L Loïc CAMPION

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

The Epidemiological Strategy and Medical Economic (ESME) Breast cancer Database is a multicenter real life database using a retrospective data collection process across 18 French comprehensive cancer centers (FCCC) spread over 20 sites. This database compiles data from patient's electronic medical records (EMR).

18 years of age All Phase N/A

CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

CATCH is an indication-specific diagnostic platform, which drives the implementation of integrative, genomic profiling for metastatic breast cancer into the clinics. The main objective of this approach is to identify biomarkers and drug targets to guide targeted therapeutic interventions. Eligible are all metastatic breast cancer patients (independent of gender), irrespective …

14 - 100 years of age All Phase N/A
A Andreas Schneeweiss, MD

COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer

The COGNITION diagnostic platform elucidates the biomarker profile of neoadjuvant chemotherapy-resistant residual bulk tumors in high risk early breast cancer patients. The major goal is to provide a framework for genomic profiling, which serves as infrastructure for systematic biomarker-screening and -stratification for concise therapy-arm allocation in the interventional clinical phase …

18 - 80 years of age All Phase N/A
A Alessandra Fabi

Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer

CYCLHER is a retrospective observational multicentric italian study aimed to evaluate the correlation between hormone receptors (HR) and HER2 immunohistochemistry (IHC) levels and treatment'response in patients affected by advanced breast cancer treated with first line CDK4/6 inhibitor plus endocrine therapy.

18 years of age All Phase N/A
Y Yunfeng Ni, MD

Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing

The goal of this observational study is to screen and differentiate common cancers in participants with or without suspicious lesions. The main question the investigators aim to answer is: Can the developed model, using peripheral blood cell-free DNA sequencing, work well in screening and classifying common cancers especially in the …

20 - 80 years of age All Phase N/A
S Saeed Jortani, Ph.D.

EXoPERT EMERALD Clinical Study

Invitro diagnostic test for multiple cancer diagnosis for patients with early-stage cancers by analyzing surface-enhanced Ramen spectroscopy (SERS) profiles of extracellular vesicles (EV) using artificial intelligence.

45 years of age All Phase N/A

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

The goal of this clinical study is to learn if serplulimab is effective in early HR+/HER2- breast cancer. This trial serves a prospective parallel control cohort for HELEN-018 (NCT). The main questions it aims to answer are: Does serplulimab combined with neoadjuvant chemotherapy improve the pCR rate of early HR+/HER2- …

18 years of age All Phase N/A

Simplify language using AI